Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.

2.

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J.

Genome Biol. 2012 Oct 3;13(10):R95. doi: 10.1186/gb-2012-13-10-r95.

3.

DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing.

Decock A, Ongenaert M, Van Criekinge W, Speleman F, Vandesompele J.

Sci Data. 2016 Feb 2;3:160004. doi: 10.1038/sdata.2016.4.

4.

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.

Kanemoto M, Shirahata M, Nakauma A, Nakanishi K, Taniguchi K, Kukita Y, Arakawa Y, Miyamoto S, Kato K.

BMC Cancer. 2014 Aug 30;14:641. doi: 10.1186/1471-2407-14-641.

5.

Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome.

Draht MX, Smits KM, Jooste V, Tournier B, Vervoort M, Ramaekers C, Chapusot C, Weijenberg MP, van Engeland M, Melotte V.

Clin Epigenetics. 2016 Apr 26;8:44. doi: 10.1186/s13148-016-0211-8. eCollection 2016.

6.

Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients.

Kuo IY, Chang JM, Jiang SS, Chen CH, Chang IS, Sheu BS, Lu PJ, Chang WL, Lai WW, Wang YC.

Int J Med Sci. 2014 May 30;11(8):779-87. doi: 10.7150/ijms.7405. eCollection 2014.

7.

Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.

Breault JE, Shiina H, Igawa M, Ribeiro-Filho LA, Deguchi M, Enokida H, Urakami S, Terashima M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):557-64.

8.

Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer.

Deng J, Liang H, Ying G, Dong Q, Zhang L, Yu J, Fan D, Hao X.

J Am Coll Surg. 2014 Nov;219(5):904-13. doi: 10.1016/j.jamcollsurg.2014.06.014. Epub 2014 Jun 26.

PMID:
25260683
9.

Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients.

Banelli B, Bonassi S, Casciano I, Mazzocco K, Di Vinci A, Scaruffi P, Brigati C, Allemanni G, Borzì L, Tonini GP, Romani M.

Int J Cancer. 2010 Feb 1;126(3):656-68. doi: 10.1002/ijc.24768.

10.

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.

Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Cañete A, Castel V, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A, Ambros PF, Beiske K, Bénard J, Marques B, Rubie H, Kohler J, Pötschger U, Ladenstein R, Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J.

Lancet Oncol. 2009 Jul;10(7):663-71. doi: 10.1016/S1470-2045(09)70154-8. Epub 2009 Jun 8.

11.

DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights.

Gómez S, Castellano G, Mayol G, Suñol M, Queiros A, Bibikova M, Nazor KL, Loring JF, Lemos I, Rodríguez E, de Torres C, Mora J, Martín-Subero JI, Lavarino C.

Epigenomics. 2015 Oct;7(7):1137-53. doi: 10.2217/epi.15.49. Epub 2015 Jun 12.

12.

Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors.

Olsson M, Beck S, Kogner P, Martinsson T, Carén H.

Epigenetics. 2016;11(1):74-84. doi: 10.1080/15592294.2016.1138195. Epub 2016 Jan 19.

13.

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.

Djos A, Martinsson T, Kogner P, Carén H.

Mol Cancer. 2012 Jun 13;11:40. doi: 10.1186/1476-4598-11-40.

14.

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.

Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund LM, Collins VP, Ichimura K.

Int J Cancer. 2012 Sep 1;131(5):1104-13. doi: 10.1002/ijc.26499. Epub 2012 Jan 11.

15.

Detection of CpG island hypermethylation of caspase-8 in neuroblastoma using an oligonucleotide array.

Kamimatsuse A, Matsuura K, Moriya S, Fukuba I, Yamaoka H, Fukuda E, Kamei N, Hiyama K, Sueda T, Hiyama E.

Pediatr Blood Cancer. 2009 Jul;52(7):777-83. doi: 10.1002/pbc.21977.

PMID:
19260109
16.

Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.

Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M.

J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19.

PMID:
15316056
17.

Combined restriction landmark genomic scanning and virtual genome scans identify a novel human homeobox gene, ALX3, that is hypermethylated in neuroblastoma.

Wimmer K, Zhu Xx XX, Rouillard JM, Ambros PF, Lamb BJ, Kuick R, Eckart M, Weinhäusl A, Fonatsch C, Hanash SM.

Genes Chromosomes Cancer. 2002 Mar;33(3):285-94.

PMID:
11807986
18.
19.

Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.

Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, Ormiston L, Ancheta K, Hanna R, Miller P, Piccioni D, Ellingson BM, Buchanan C, Mischel PS, Nghiemphu PL, Green R, Wang HJ, Pope WB, Liau LM, Elashoff RM, Cloughesy TF, Yong WH, Lai A.

Neuro Oncol. 2013 Mar;15(3):370-81. doi: 10.1093/neuonc/nos308. Epub 2013 Jan 17.

20.

Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas.

Siu LL, Chan JK, Wong KF, Choy C, Kwong YL.

Br J Haematol. 2003 Jul;122(1):70-7.

PMID:
12823347

Supplemental Content

Support Center